Ruxolitinib in severe COVID-19: Results of a multicenter, prospective, single arm, open-label clinical study to investigate the efficacy and safety of ruxolitinib in patients with COVID-19 and severe acute respiratory syndrome

Introduction: COVID-19 morbimortality is mainly associated with development of severe acute respiratory syndrome (SARS), which has been related to an augmented immune response of the host with elevated circulating cytokines. Methods: In this is a prospective, multicenter, single arm (compared with a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Iastrebner, Marcelo, Castro, Joaquín, García Espina, Edgardo, Lettieri, Carolina, Payaslian, Silvio, Cuesta, María Celia, Gutiérrez Fernández, Pablo, Mandrile, Araceli, Contreras, Angela Paola, Gervasoni, Sebastián, Verde, Gabriel, Galetti, Cayetano, Minoldo, Estefanía, Caruso, Vanesa
Formato: Artículo revista
Lenguaje:Inglés
Publicado: Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2021
Materias:
coronavirus infections
Janus kinase inhibitors
respiratory distress syndrome, adult
infecciones por coronavirus
inhibidores de las cinasas Janus
síndrome de dificultad respiratoria del adulto
infecções por coronavirus
inibidores de janus quinases
síndrome do desconforto respiratório do adulto
Acceso en línea:https://revistas.unc.edu.ar/index.php/med/article/view/32800
Aporte de:
Revista de la Facultad de Ciencias Médicas de Córdoba de Universidad Nacional de Córdoba

Ejemplares similares

Ejemplares similares